Announcements Trials
Browse Landscape

Phase

Phase 1 136Phase 2 95Phase 1/2 91Phase 3 72Phase 2/3 5Phase EARLY_PHASE1 4Phase 4 3Phase NA 2

Status

Completed 2Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 6INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 27Neoplasms 22Breast Neoplasms 20Neoplasm Metastasis 18Colorectal Neoplasms 16Stomach Neoplasms 15Recurrence 15Prostatic Neoplasms 15Carcinoma, Hepatocellular 12Pancreatic Neoplasms 11Ovarian Neoplasms 11Head and Neck Neoplasms 11Squamous Cell Carcinoma of Head and Neck 10Lung Neoplasms 10Myasthenia Gravis 9Melanoma 9Leukemia, Myeloid, Acute 9Urinary Bladder Neoplasms 8Lymphoma, Large B-Cell, Diffuse 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Multiple Myeloma 6Lymphoma, Non-Hodgkin 6Liver Neoplasms 6Cholangiocarcinoma 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Small Cell Lung Carcinoma 5Lymphoma, Follicular 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Leukemia 5

Interventions

Drug Therapy 2dinutuximab 1atezolizumab 1Topotecan 1SR 48692 1Rabeprazole 1Irinotecan 1EC regimen 1E-3810 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Small Cell Lung Carcinoma × Clear all
NCT07226999 2026-04-20

Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

Pfizer

Phase 2/3 Recruiting
550 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT01064466 2025-07-24

Drugs-SNPs

Medicine Invention Design, Inc

Phase 2/3 Active not recruiting
600 enrolled
Thoracic

Neoplasms, Small Cell Lung Carcinoma

NCT03098030 2020-12-09

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

United Therapeutics

Phase 2/3 Completed
483 enrolled 19 charts
Thoracic

Small Cell Lung Carcinoma

NCT04254471 2020-02-05

This Phase II/III, Multicenter Study is Designed to Evaluate the Safety and Clinical Activity of AL3810 in Patients

Haihe Biopharma Co., Ltd.

Phase 2/3 Unknown
313 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT00290953 2008-12-23

SESAME

Sanofi

Phase 2/3 Completed
432 enrolled
Thoracic

Lung Neoplasms, Neoplasm Metastasis, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡